Nanozyme therapies for PD aim to reduce oxidative stress by scavenging ROS with the subsequent result of stopping α-synuclein pathologic propagation or decreasing the neuroinflammatory response to prevent nigrostriatal neuronal death. Here, SNCA is linked to Parkinson disease.